- Home
- IMAB vs ANVS Comparison
IMAB vs ANVS Comparison
Compare IMAB & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ANVS
- Stock Information
- Founded
- IMAB 2014
- ANVS 2008
- Country
- IMAB United States
- ANVS United States
- Employees
- IMAB N/A
- ANVS N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- ANVS Health Care
- Exchange
- IMAB Nasdaq
- ANVS Nasdaq
- Market Cap
- IMAB 83.8M
- ANVS 92.6M
- IPO Year
- IMAB 2020
- ANVS 2020
- Fundamental
- Price
- IMAB $0.94
- ANVS $5.04
- Analyst Decision
- IMAB Strong Buy
- ANVS Strong Buy
- Analyst Count
- IMAB 3
- ANVS 6
- Target Price
- IMAB $8.00
- ANVS $29.67
- AVG Volume (30 Days)
- IMAB 288.7K
- ANVS 294.5K
- Earning Date
- IMAB 08-28-2024
- ANVS 11-08-2024
- Dividend Yield
- IMAB N/A
- ANVS N/A
- EPS Growth
- IMAB N/A
- ANVS N/A
- EPS
- IMAB N/A
- ANVS N/A
- Revenue
- IMAB $3,313,984.00
- ANVS N/A
- Revenue This Year
- IMAB N/A
- ANVS N/A
- Revenue Next Year
- IMAB N/A
- ANVS N/A
- P/E Ratio
- IMAB N/A
- ANVS N/A
- Revenue Growth
- IMAB N/A
- ANVS N/A
- 52 Week Low
- IMAB $0.90
- ANVS $4.53
- 52 Week High
- IMAB $2.54
- ANVS $22.49
- Technical
- Relative Strength Index (RSI)
- IMAB 38.29
- ANVS 32.21
- Support Level
- IMAB $0.91
- ANVS $4.76
- Resistance Level
- IMAB $1.11
- ANVS $6.37
- Average True Range (ATR)
- IMAB 0.07
- ANVS 0.50
- MACD
- IMAB -0.00
- ANVS -0.05
- Stochastic Oscillator
- IMAB 13.01
- ANVS 14.45
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.